Axillary reverse mapping (ARM) in clinically node positive breast cancer patients

European Journal of Surgical Oncology

Volumn 41, Issue 1, 2015, Pages 59-63

  Beek, M A ^a   Gobardhan, P D ^a   Klompenhouwer, E G ^b   Rutten, H J T ^b,c   Voogd, A C ^d,e   Luiten, E J T ^a  

^a AMPHIA HOSPITAL   (Netherlands)

^b CATHARINA HOSPITAL   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e Eindhoven Cancer Registry   (Netherlands)

Author keywords

Axillary reverse mapping; Breast cancer; Lymphedema

Indexed keywords

ANTINEOPLASTIC AGENT; COLORING AGENT;

ADULT; ARTICLE; ASPIRATION CYTOLOGY; AXILLARY LYMPH NODE; AXILLARY REVERSE MAPPING; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MIDDLE AGED; PRIORITY JOURNAL; RISK ASSESSMENT; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AGED; ARM; AXILLA; BREAST NEOPLASMS; CARCINOMA; DIAGNOSTIC USE; LYMPH NODE; LYMPH VESSEL; LYMPHEDEMA; PATHOLOGY; PROCEDURES; PROSPECTIVE STUDY;

ADULT; AGED; AXILLA; BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; COLORING AGENTS; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC VESSELS; LYMPHEDEMA; MIDDLE AGED; NEOADJUVANT THERAPY; PROSPECTIVE STUDIES; UPPER EXTREMITY;

EID: 84922569463     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2014.09.012     Document Type: Article

References (30)

1. Maaskant AJ, van de Poll-Franse LV, Voogd AC, Coebergh JW, Tutein-Nolthenius-Puylaert MC, Nieuwenhuijzen GA. Stage migration due to introduction of the sentinel node procedure: A population-based study. Breast Cancer Res Treat 2009 Jan;113(1):173-9. [PubMed PMID: 18259855].
2. Tausch C, Baege A, Dietrich D, et al. Can axillary reverse mapping avoid lymphedema in node positive breast cancer patients? Eur J Surg Oncol 2013 Aug;39(8):880-6. [PubMed PMID: 23735162].
3. Noguchi M, Miwa K, Michigishi T, et al. The role of axillary lymph node dissection in breast cancer management. Breast Cancer 1997 Oct 31;4(3):143-53. [PubMed PMID: 11091589].
4. Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 2006 May 3;98(9):599-609. [PubMed PMID: 16670385].
5. Blanchard DK, Donohue JH, Reynolds C, Grant CS. Relapse and morbidity in patients undergoing sentinel lymph node biopsy alone or with axillary dissection for breast cancer. Archives Surg 2003 May;138(5):482-7. [discussion 7-8. PubMed PMID: 12742949].
6. Haid A, Koberle-Wuhrer R, Knauer M, et al. Morbidity of breast cancer patients following complete axillary dissection or sentinel node biopsy only: A comparative evaluation. Breast Cancer Res Treat 2002 May;73(1):31-6. [PubMed PMID: 12083629].
7. Leidenius M, Leivonen M, Vironen J, von Smitten K. The consequences of long-time arm morbidity in node-negative breast cancer patients with sentinel node biopsy or axillary clearance. J Surg Oncol 2005 Oct 1;92(1):23-31. [PubMed PMID: 16180231].
8. Ronka R, von Smitten K, Tasmuth T, Leidenius M. One-year morbidity after sentinel node biopsy and breast surgery. Breast 2005 Feb;14(1):28-36. [PubMed PMID: 15695078].
9. Schijven MP, Vingerhoets AJ, Rutten HJ, et al. Comparison of morbidity between axillary lymph node dissection and sentinel node biopsy. Eur J Surg Oncol 2003 May;29(4):341-50. [PubMed PMID: 12711287].
10. Schrenk P, Rieger R, Shamiyeh A, Wayand W. Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer 2000 Feb 1;88(3):608- 14. [PubMed PMID: 10649254].
11. Swenson KK, Nissen MJ, Ceronsky C, Swenson L, Lee MW, Tuttle TM. Comparison of side effects between sentinel lymph node and axillary lymph node dissection for breast cancer. Ann Surg Oncol 2002 Oct;9(8):745-53. [PubMed PMID: 12374657].
12. Nos C, Kaufmann G, Clough KB, et al. Combined axillary reverse mapping (ARM) technique for breast cancer patients requiring axillary dissection. Ann Surg Oncol 2008 Sep;15(9):2550-5. [PubMed PMID: 18618185].
13. Thompson M, Korourian S, Henry-Tillman R, et al. Axillary reverse mapping (ARM): A new concept to identify and enhance lymphatic preservation. Ann Surg Oncol 2007 Jun;14(6):1890-5. [PubMed PMID: 17479341].
14. Klimberg VS. A new concept toward the prevention of lymphedema: Axillary reverse mapping. J Surg Oncol 2008 Jun 1;97(7):563-4. [PubMed PMID: 17955452].
15. Ponzone R, Cont NT, Maggiorotto F, et al. Extensive nodal disease may impair axillary reverse mapping in patients with breast cancer. J Clin Oncol 2009 Nov 20;27(33):5547-51. [PubMed PMID: 19826123].
16. Boneti C, Korourian S, Diaz Z, et al. Scientific impact award: Axillary reverse mapping (ARM) to identify and protect lymphatics draining the arm during axillary lymphadenectomy. Am J Surg 2009 Oct; 198(4):482-7. [PubMed PMID: 19800452].
17. Casabona F, Bogliolo S, Valenzano-Menada M, Sala P, Villa G, Ferrero S. Feasibility of axillary reverse mapping during sentinel lymph node biopsy in breast cancer patients. Ann Surg Oncol 2009 Sep;16(9):2459-63. [PubMed PMID: 19506954].
18. Deng H, Chen L, Jia W, et al. Safety study of axillary reverse mapping in the surgical treatment for breast cancer patients. J Cancer Res Clin Oncol 2011 Dec;137(12):1869-74. [PubMed PMID: 21935615].
19. Gobardhan PD, Wijsman JH, van Dalen T, et al. ARM: Axillary reverse mapping e the need for selection of patients. Eur J Surg Oncol 2012 Aug;38(8):657-61. [PubMed PMID: 22607749].
20. Boneti C, Korourian S, Bland K, et al. Axillary reverse mapping: mapping and preserving arm lymphatics may be important in preventing lymphedema during sentinel lymph node biopsy. J Am Coll Surg 2008 May;206(5):1038-42. [discussion 42-4. PubMed PMID: 18471751].
21. Noguchi M, Yokoi M, Nakano Y. Axillary reverse mapping with indocyanine fluorescence imaging in patients with breast cancer. J Surg Oncol 2010 Mar 1;101(3):217-21. [PubMed PMID: 20063370].
22. Nos C, Lesieur B, Clough KB, Lecuru F. Blue dye injection in the arm in order to conserve the lymphatic drainage of the arm in breast cancer patients requiring an axillary dissection. Ann Surg Oncol 2007 Sep; 14(9):2490-6. [PubMed PMID: 17549570].
23. Ponzone R, Mininanni P, Cassina E, Sismondi P. Axillary reverse mapping in breast cancer: can we spare what we find? Ann Surg Oncol 2008 Jan;15(1):390-1. [author reply 2-3. PubMed PMID: 17990039].
24. Boneti C, Badgwell B, Robertson Y, Korourian S, Adkins L, Klimberg V. Axillary reverse mapping (ARM): initial results of phase II trial in preventing lymphedema after lymphadenectomy. Minerva Ginecol 2012 Oct;64(5):421-30. [PubMed PMID: 23018481].
25. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991 Nov; 19(5):403-10. [PubMed PMID: 1757079].
26. NOABON. Landelijke richtlijn mammacarcinoom 2.0. www.oncolinenl/mammacarcinoom.
27. Casabona F, Bogliolo S, Ferrero S, Boccardo F, Campisi C. Axillary reverse mapping in breast cancer: A new microsurgical lymphaticvenous procedure in the prevention of arm lymphedema. Ann Surg Oncol 2008 Nov;15(11):3318-9. [PubMed PMID: 18709416].
28. Bedrosian I, Babiera GV, Mittendorf EA, et al. A phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients. Cancer 2010 Jun 1;116(11):2543-8. [PubMed PMID: 20336790].
29. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A randomized clinical trial. J Am Med Assoc 2011 Feb 9;305(6):569-75. [PubMed PMID: 21304082].
30. Klompenhouwer EG, Gobardhan PD, Beek MA, Voogd AC, Luiten EJ. The clinical relevance of axillary reverse mapping (ARM): study protocol for a randomized controlled trial. Trials 2013;14:111. [PubMed PMID: 23782712. Pubmed Central PMCID: 3663653].